IP Library Granted Patent US 9,956,254
Granted Patent B2
US 9,956,254 · App. 14/632,894 · Granted May 1, 2018

Extract of taiwanese propolis for treating ocular diseases

Inventor: Chi Chou Liao (Taipei, TW)
Assignee: NATUREWISE BIOTECH & MEDICALS CORPORATION
A61K35/644
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,956,254
App. No.
14/632,894
Granted
May 1, 2018
Kind
B2
Abstract

The present invention provides a method for treating an ocular disease in a subject in need thereof, comprising administering an effective amount of an extract of Taiwanese propolis (TP) or an active component thereof to the subject. Also provided is a pharmaceutical composition for treating an ocular disease, which comprises an effective amount of an extract of TP or an active component thereof, and a pharmaceutically acceptable carrier.

Claims (16)

1. A method for treating an ocular disease in a subject in need thereof, comprising

administering to the subject an extract of Taiwanese propolis (TPE) in an amount effective to enhance the viability of RPE cells suffering from oxidative stress and/or hypoxia-induced damages, and at the same time having little or no effect on the viability of human umbilical vein endothelial cells (HUVECs),

wherein the TPE is prepared from Taiwanese propolis by a method comprising the following steps:

(i) extracting Taiwanese propolis with 95% ethanol for about 48 hours at 45° C. to obtain a first extract;

(ii) collecting a soluble fraction of the first extract containing propolins; and

(iii) concentrating the soluble fraction by about 4 times to obtain the TPE,

whereby each gram of TPE contains no less than 100 mg of propolin C, 80 mg of propolin D, 30 mg of propolin F and 50 mg of propolin G, and each gram of TPE contains no less than 350 mg of total propolins.

2. The method of claim 1 , wherein the ocular disease is selected from the group consisting of glaucoma, age-related macular degeneration (AMD), ischemic retinopathy, optic neuropathy, diabetic retinopathy, diabetic macular edema, uveitis, and senile cataract.

3. The method of claim 2 , wherein the ocular disease is AMD.

4. The method of claim 3 , wherein the AMD is dry AMD.

5. The method of claim 1 , wherein the TPE is administered through oral administration, parenteral injection, intravitreal injection, or skin patch.

6. The method of claim 1 , wherein the TPE is formulated into eye ointment, eye gel, eye cream, or eye drops.

7. The method of claim 1 , wherein the ocular disease is not an eye cancer.

8. The method of claim 1 , wherein the Taiwanese propolis is Taiwanese green propolis.

9. The method of claim 1 , wherein the TPE is administered orally to the subject 1-3 times a day, with each oral administration of having an amount of the TPE of 10-200 mg.

10. The method of claim 1 , wherein the TPE is administered ophthalmologically to the subject 1-10 times daily, with each ophthalmological administration using a solution of 0.01-10% TPE.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Mar 23, 2018
From: SPRINGSKY BIOMED COMPANY LIMITED; NATUREWISE BIOTECH & MEDICALS CORPORATION
To: NATUREWISE BIOTECH & MEDICALS CORPORATION
Reel/Frame 045324/0867 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2018
From: LIAO, CHI CHOU
To: SPRINGSKY BIOMED LIMITED COMPANY
Reel/Frame 044653/0699 →
Continuity (1)
Related Publication 20160250264A1 · Sep 1, 2016